High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This trial will examine the effectiveness and the side effects of 2 higher dosing schedules
of bevacizumab in patients that have advanced clear cell renal carcinoma.